Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?

The Zacks Focus List offers investors a way to easily find top-rated stocks and build a winning investment portfolio. Here's why you should take advantage.

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.

The Zacks Focus List offers investors a way to easily find top-rated stocks and build a winning investment portfolio. Here's why you should take advantage.

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

Sarepta Therapeutics (SRPT) sold off more than 40% after suspending its Elevidys Duchenne muscular dystrophy drug, which was linked to two fatal liver failure cases. Diane King Hall break takes a closer look into the report.

HOMEWOOD, Ill., June 16, 2025 (GLOBE NEWSWIRE) -- CN (TSX: CNR) (NYSE: CNI) announced today plans to invest approximately US$85 million in Michigan, as part of its 2025 capital investment program. This investment will support track maintenance and strategic infrastructure initiatives in the state. This includes projects to build intermodal capacity and upgrades to improve operations at CN's Lansing, Battle Creek and Flint railyards. These projects will help ensure the safe movement of goods and support long-term sustainable growth in Michigan and across CN's network.

Spectrum Has Provided $1.8 Million in College Scholarships Through Spectrum Scholars Since 2020 Key Takeaways: 15 college students awarded $20,000 each in scholarships. Spectrum Scholars provides access to mentorship, networking and a Spectrum internship.

NEW YORK, NY / ACCESS Newswire / June 16, 2025 / If you suffered a loss on your Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/rocket-pharmaceuticals-inc-lawsuit-submission-form?prid=153290&wire=1&utm_campaign=13 or contact Joseph E. Levi, Esq.

NEW YORK, NY / ACCESS Newswire / June 16, 2025 / If you suffered a loss on your NET Power, Inc. (NYSE:NPWR) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/net-power-inc-lawsuit-submission-form?prid=153294&wire=1&utm_campaign=17 or contact Joseph E. Levi, Esq.

LOS ANGELES , June 16, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Krispy Kreme, Inc. ("Krispy Kreme" or "the Company") (NASDAQ: DNUT) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 25, 2025 and May 7, 2025, inclusive (the "Class Period"), are encouraged to contact the firm before July 15, 2025.

LOS ANGELES , June 16, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Iovance Biotherapeutics, Inc. ("Iovance" or "the Company") (NASDAQ: IOVA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between May 9, 2024 and May 8, 2025, inclusive (the "Class Period"), are encouraged to contact the firm before July 14, 2025.

Cantor Fitzgerald analyst Andres Sheppard has reaffirmed a ‘Neutral' rating on Lucid Group stock (NASDAQ: LCID), citing the company's strengthening supply chain as a key factor.

TSLA unveils updated Model S and X with modest upgrades and $5,000 price hikes amid rising competition.

Jabil targets fiscal Q3 revenue growth fueled by AI, cloud and data center momentum, with innovation and cash flow in focus.

NEW YORK, NY / ACCESS Newswire / June 16, 2025 / If you suffered a loss on your UroGen Pharma Ltd. (NASDAQ:URGN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/urogen-pharma-ltd-lawsuit-submission-form?prid=153258&wire=1&utm_campaign=28 or contact Joseph E.

NEW YORK, NY / ACCESS Newswire / June 16, 2025 / If you suffered a loss on your Fortrea Holdings Inc. (NASDAQ:FTRE) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/fortrea-holdings-inc-lawsuit-submission-form?prid=153289&wire=1&utm_campaign=5 or contact Joseph E. Levi, Esq.

NEW YORK, NY / ACCESS Newswire / June 16, 2025 / If you suffered a loss on your DoubleVerify Holdings, Inc. (NYSE:DV) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/doubleverify-holdings-inc-lawsuit-submission-form-2?prid=153260&wire=1&utm_campaign=12 or contact Joseph E. Levi, Esq.